Quantcast

Latest Prostate-specific antigen Stories

2012-04-30 05:26:42

Despite recommendations in 2008 from the United States Preventive Services Task Force against testing for prostate cancer in men aged 75 years or older, almost half of men in that age group continue to get screening tests. In 2005, before the recommendations were released, 43 percent of men age 75 and above elected to take the prostate-specific antigen (PSA) test. In August 2008, the Task Force stated it "recommends against the service," arguing "there is moderate or high certainty the...

2012-04-09 21:46:42

Discovery of inherited-genetic variations may help assess a patient's risk of life-threatening disease before it strikes An international research team led by Weill Cornell Medical College investigators have discovered two inherited-genetic deletions in the human genome linked to development of aggressive prostate cancer. The findings, published online today in the Proceedings of the National Academy of Sciences (PNAS), indicate a man's risk of developing prostate cancer either triples or...

2012-04-09 05:40:35

(Ivanhoe Newswire) -- Do you or someone you know suffer from advanced prostate cancer (CRPC)? A new treatment may be available that can help treat the deadly disease. Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. A drug called galeterone works against CRPC by blocking the androgen receptor, reducing levels of the ligand that binds to the receptor and degrading...

2012-04-02 09:22:59

Phase 1 data presented at AACR Annual Meeting 2012; Study showed no dose limiting toxicities with galeterone; Preliminary efficacy data reported Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be...

2012-04-02 09:16:50

Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4. Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. Galeterone works against...

2012-03-16 05:44:37

(Ivanhoe Newswire)-- Prostate cancer is the most common cause of death from cancer in men over age 75. An 11 year study looked at death in men whom prostate cancer was diagnosed pre death and post death. The study consisted of 182,160 men between the ages of 50 and 74 years at the start of the study, with a predefined core age group of 162,388 men 55 to 69 years of age. The trial was conducted in eight European countries. Men who were randomly assigned to the screening group were...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related